In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Oriol CalveteMDS Research Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.
Julia MestreMDS Research Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.ORCID 0000-0002-4809-3897 Lurdes ZamoraHaematology Department, Hospital Germans Trias i Pujol-Institut Català d'Oncologia, 08916 Badalona, Spain.ORCID 0000-0003-1713-7110 Lorea Chaparro-GonzálezMDS Research Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.
Lucía Ruiz Pérez-HitaMDS Research Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.
Sara Torres-EsquiusHaematology Department, Vall d'Hebrón Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebrón, 08035 Barcelona, Spain.
María Julia MontoroHaematology Department, Vall d'Hebrón Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebrón, 08035 Barcelona, Spain.
Blanca XicoyHaematology Department, Hospital Germans Trias i Pujol-Institut Català d'Oncologia, 08916 Badalona, Spain.ORCID 0000-0002-0295-1307 Francesc SoléMDS Research Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.ORCID 0000-0002-3251-2161 Funding
European Regional Development Fund PI23/00007European Social Funding Plus (FSE+) 2023 FI-1 00200Generalitat de Catalunya 2021 SGR0056Instituto de Salud Carlos III PI23/00007Instituto de Salud Carlos III PMP24/00025Joan Oró predoctoral programla Fundación Española de Hematología y Hemoterapia (FEHH)
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
CD3+ VAFinitiation mutationsmulti-compartmental mutationsmyeloid-restricted mutationsprogenitor mutationsSF3B1 p.K700E hotspot
Identifiers
PMID42073631
PMCPMC13114748
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390